Short Stature in Isodicentric Y Chromosome and Three Copies of the *SHOX* Gene: Clinical Report and Review of Literature

Angelo Valetto^a Veronica Bertini^a Angela Michelucci^a Benedetta Toschi^a
Eleonora Dati^c Giampietro I. Baroncelli^b Silvano Bertelloni^b

^aDivision of Cytogenetic and Molecular Biology and ^bAdolescent Medicine, Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana (AOUP), Pisa, and ^cDivision of Pediatrics, San Giuseppe Hospital, ASL 11, Empoli, Italy

Key Words

GH-IGF1 axis · Short stature · *SHOX* · *SHOX* duplications · Y chromosome rearrangement

Abstract

Short stature homeobox gene (*SHOX*) mutations and pseudoautosomal region 1 (PAR1) deletions encompassing *SHOX* are known causes of Léri-Weill dyschondrosteosis and isolated short stature, while 3 copies of *SHOX* in cases with triple sex chromosome constitution are responsible for tall stature. Duplications involving *SHOX* have been rarely reported, and they were found in individuals with short, normal and tall stature. An adopted boy with short stature, isodicentric Y chromosome and 3 copies of *SHOX* is described. Normal growth hormone (GH) secretion and insulin-like growth factor 1 (IGF1) increase during an IGF1 generation test were found, ruling out impaired GH-IGF1 axis. No other organic or psychiatric causes of impaired growth were found. GH treatment improved linear growth, as reported in children with *SHOX* haploinsufficiency. This new report and the review of literature support that *SHOX* duplication may cause short stature, especially in those children with duplications of the 5' *SHOX* regulatory elements. Chromosome analysis and detailed molecular characterization of the duplicated region

should be warranted in individuals with *SHOX* duplications in order to investigate the presence of occult chromosome imbalance. Additional reports and follow-up till adult height are needed to give conclusions on long-term efficacy and safety of GH treatment in short children with *SHOX* duplication.

© 2016 S. Karger AG, Basel

The short stature homeobox gene (*SHOX*; NM_00451) encodes a homeodomain transcription factor involved in the regulation of chondrocyte differentiation and proliferation; it plays an important role in human skeletal growth, being specifically expressed in the growth plate [Marchini et al., 2007; Binder, 2011]. *SHOX* is located in the pseudoautosomal region 1 (PAR1) of the human sex chromosomes (Xp22.3 and Yp11.3). PAR1 genes do not undergo X inactivation and 2 copies of the *SHOX* gene are expressed, one from each of the sex chromosomes [Marchini et al., 2007; Iughetti et al., 2009; Binder, 2011].

Subjects with monoallelic mutations or deletions within the *SHOX* coding or enhancer regions have variable

A.V. and V.B. equally contributed to the genetic characterization of isodicentric Y chromosome and the discussion on genetics.

Table 1. Clinical data at adoption, at first clinical evaluation and during follow-up

	Adoption	First visit	GH		
			start	6 months	12 months
Age, years	3.4/12	9.6/12	10.7/12	11.1/12	11.7/12
Height, cm (SD)	86.0 (–3.1)	118.8 (–2.7)	123.0 (–2.8)	128.3 (–2.3)	132.6 (–2.1)
Sitting/standing height ratio (percentile)	–	0.532 (97th)	0.535 (97th)	0.527 (97th)	0.525 (97th)
Weight, kg	9.9	26.0	30.6	31.7	32.5
BMI (SD)	13.4 (–1.75)	18.4 (1.1)	20.2 (1.5)	19.2 (1.0)	18.5 (0.5)

degrees of growth impairment, with or without the spectrum of skeletal anomalies consistent with the mesomelic skeletal dysplasia known as Léri-Weill dyschondrosteosis (LWD) [Iughetti et al., 2009; Binder, 2011]. *SHOX* haploinsufficiency has been found in 60–90% of patients with LWD and in 5–17% of children diagnosed as idiopathic short stature [Huber et al., 2006; Rappold et al., 2007; Rosilio et al., 2012; Wolters et al., 2013]. Patients with extra copies of *SHOX* due to sex chromosome trisomies are usually characterized by tall stature [Aksglaede et al., 2008], supporting the dosage-dependent action of *SHOX* on growth [Marchini et al., 2007; Iughetti et al., 2009; Binder, 2011].

Whereas patients with triple sex chromosome constitution are relatively common, complete or partial duplications limited to PAR1 including *SHOX* are extremely rare. Duplications of *SHOX* have been described in individuals with short, normal or tall stature [Roos et al., 2009; Thomas et al., 2009; D’haene et al., 2010; Iughetti et al., 2010; Benito-Sanz et al., 2011], leading to some uncertainty on the effect of *SHOX* duplication on growth.

Here, a boy with impaired growth and 3 copies of *SHOX*, due to a Y-chromosome rearrangement is described.

Clinical Report

The boy of Brazilian origin was born after an uncomplicated pregnancy and adopted by Italian parents when he was 3 years old. Normal birth weight was affirmed in his clinical record, but raw values and auxological data from his parents were not available.

Auxological data at adoption are summarized in table 1 showing impaired linear growth and body weight. The boy came to our attention on account of short stature at the age of 9.5 years. His weight and body mass index (BMI) were normal, but he did not reach adequate height for his age (table 1). He had mild cubitus valgus and a short neck, but Madelung deformity was not present. The sitting height/standing height ratio was at the 97th percentile

(table 1), suggesting body disproportion because of abnormal leg length. Bone age was 9.0 years (–0.96 SD), carpal and epiphyseal angles were 135° (n.v. <120°) and 20° (n.v. <15°), respectively [Iughetti et al., 2010].

The occurrence of occult celiac disease or other chronic gastrointestinal disorder was ruled out by appropriate biochemical analysis; C-reactive protein, thyroid values, renal function, and albumin levels were normal (data not shown). Growth hormone (GH) deficiency was not found (GH peaks >10 ng/ml during 2 provocative GH tests). IGF1 values were in the normal range, but below the mean for age and sex (114.0 ng/ml; –0.62 SD). A normal increase was found after a IGF1 generation test (peak IGF1 value 331.2 ng/ml; Δ -increase + 190%, n.v. >15%) [Pessoa de Queiroz et al., 2007]. No psychiatric causes of impaired growth were found.

Methods

Clinical and Endocrine Evaluation

Standing height was measured with a wall-mounted stadiometer. SD score of height and BMI [weight (kg)/height (m²)] was calculated according to WHO standards (www.who.int/childgrowth/standards/en/). Sitting height/standing height ratio was evaluated according to Spanish normative values [de Arriba Muñoz et al., 2013]. Bone age was determined using X-ray of the nondominant hand and wrist and estimated according to Greulich and Pyle [1959]. Blood samples were drawn in the morning (between 8.00 and 9.00 a.m.), and serum was stored at –20°C until analysis. Hormonal assays were performed by commercially available ELISA and chemiluminescence kits.

Cytogenetic Analysis

G- and Q-banded chromosomes of cultured peripheral blood lymphocytes and 100 metaphases were analyzed. Briefly, whole blood was cultivated in RPMI-1640 (Celbio, Milan, Italy), supplemented with 2% glutamine, 10% fetal calf serum, and 2% w/v PHA-M (Sigma, St. Louis, Mo., USA) for 72 h at 37°C. Chromosome preparations were obtained according to standard techniques.

FISH and Chromosome Painting

FISH studies were performed at standard conditions using a whole Y chromosome-painting probe as well as probes specific for *SRY* and *CEPX/CEPY* centromere (Cytocell, Cambridge,

Fig. 1. Chromosome constitution of the boy with triple SHOX. **a** Q-banded karyotype showing the idic(Y). **b** Scheme of the structure of a normal Y chromosome and an idic(Y) chromosome.

UK). Each experiment was carried out according to the manufacturer's instructions. Signals were visualized by a Nikon microscope with an epifluorescent illuminator (Nikon, Tokyo, Japan) and were digitized for documentation with the CytoVision system (Nikon).

Multiple Ligation Probe Assay

MLPA reagents were obtained from MRC-Holland, Amsterdam, The Netherlands (SALSA MLPA kit P018-F1 SHOX). About 100 ng of genomic DNA was used in the test, according to the manufacturer's protocol. Data normalization and data analysis were performed according to the manufacturer's recommendation.

Array CGH

Array CGH was performed according to standard protocols. Briefly, genomic DNA was extracted from peripheral blood lymphocytes of the patient. This DNA and a male reference DNA were labeled differentially with cyanine 3 and 5, using standard procedures. Microarray experiments were performed on DNA microarrays 8x60K (Agilent Technologies, Santa Clara, Calif., USA) that have an ~25-kb average probe spatial resolution. Microarrays were scanned with an Agilent scanner G256BA. Hybridization data analysis was carried out with Agilent Technologies dedicated software. Search for copy number variation regions was performed using the Database of Genomic Variants (<http://projects.tcag.ca/variation/>).

Results

A derivative Y chromosome was detected in all examined metaphases of the patient. FISH using a Y chromosome-painting probe confirmed the Y origin of this chromosome. *SRY* probe showed 2 hybridization signals, and 2 signals were apparent after hybridization with an alpha-centromeric Y probe. PCR analysis showed that the azoospermia factor regions were present. The final karyotype was 46,X,idic(Y,Y)(qter→p11.32::p11.32→qter).ish idic(Y,Y)(qter→p11.32::p11.32→qter)(*SRY*++,*DYZ3*++). The structure of idic(Y) is shown in figure 1.

MPLA showed an increase of about 50% of the peak areas corresponding to the probes in the PAR1. The probes from 01341-L20651 to 16858-L15742 were duplicated, including the *SHOX* gene (P018-F1 SALSA MLPA Kit). Sequencing of the coding region of *SHOX* did not detect any mutations.

Array CGH detected a 248-kb deletion starting from 11,091 to 248,336 (Yp11.32) and a 58-Mb duplication starting from position 248,336 (Yp11.32) to 59,335,913 (Yq12) (Hg19 reference map).

After diagnosis of the *SHOX* duplication, treatment with recombinant GH was started at the dose of 0.33 mg/kg/week and subdivided in 7 weekly doses. Growth velocity at 6 months (10.6 cm/year) and 12 months (8.6 cm/year) of follow-up clearly increased in comparison with the value before the beginning of GH administration (4.2 cm/year). A reduction of the growth deficit and a decrease in the slight overweight were recorded during follow-up (table 1). No abnormal progression of bone age was observed (start of GH therapy: -0.80 SD; 12 months follow-up: -0.62 SD).

Discussion

In this report, a child with short stature and 3 copies of *SHOX* is described. He was adopted from a low-income social area, and malnutrition may be involved in both low weight and height at the age 3 years [Rogol and Hayden, 2014]. While BMI progressively normalized after adoption, height did not, suggesting the possibility of a specific cause for his short stature. Extensive investigations ruled out common organic or psychiatric causes of short stature [Rogol and Hayden, 2014; Ghione et al., 2015], not always explored in the previous short patients with *SHOX* duplications [D'haene et al., 2010; Iughetti et al., 2010; Benito-Sanz et al., 2011]. Normal GH secretion was found in the case reported by Iughetti et al. [2010]. In the patient of D'haene et al. [2010], data of clinical and endocrine investigations were not shown. In the series of Benito-Sanz et al. [2011], the children were investigated according to criteria requiring the exclusion of GH deficiency [Cohen et al., 2008]. In the present case, normal GH secretion was also found. The normal increase in IGF1 during an IGF1 generation test, previously unreported in short patients with *SHOX* duplications, indicates normal GH sensitivity [Pessoa de Queiroz et al., 2007; Bertelloni et al., 2013].

So, the patient's karyotype constitution [46,X,idic(Y)(p11.3)] may be involved in the origin of short stature. Different mechanisms can be proposed for the formation of this idic(Y), both of them take place during the first meiotic division. The first mechanism involves a terminal deletion in Yp11.3, resulting in the loss of the telomeric Yp and in an unstable chromosome. End fusion of the 2 broken chromatids may occur to stabilize the deleted chromosome, followed by misdivision of the centromere (fig. 2). The second mechanism involves a misalignment between palindromic sequences in Y PAR1 along sister chromatids, that mediate a NAHR. The acentric fragment

is likely lost during cell divisions (fig. 2a, b) [Lange et al., 2009].

The array CGH showed that the breakpoint of the idic(Y) is quite close to the Yp telomere, causing the deletion of 248 kb of the distal portion of PAR1 region. This region does not harbor known genes, whose deletion has been associated with pathological phenotypes. The rearranged idic(Y) chromosome (fig. 1) carries 2 copies of *SHOX*, leading to a trisomy of the gene. People with triple *SHOX* due to sex chromosome trisomy usually show tall stature [Aksglaede et al., 2008]. This finding is not always true in individuals with microduplications of PAR1 involving *SHOX* or its regulatory sequences. In fact, cases with tall, normal and short stature have been reported [Roos et al., 2009; Thomas et al., 2009; D'haene et al., 2010; Iughetti et al., 2010; Benito-Sanz et al., 2011; Brosens et al., 2014].

The impaired growth pattern of some individuals with isolated *SHOX* microduplications suggests that expression of the allele harboring the duplication may be reduced or ablated, resulting in functional *SHOX* haploinsufficiency [Benito-Sanz et al., 2011]. The breakpoint of the microduplications can alter or disrupt its complex transcriptional regulation, in which either specific 5' or 3' regulatory sequences are involved for optimal gene expression [Ellison et al., 1997; Rao et al., 1997; Blaschke et al., 2003]. Regulatory sequences, such as enhancer elements, have been located in the proximity both of the 5' and the 3' gene regions, and they are necessary for temporal- and tissue-specific *SHOX* expression [Rosin et al., 2013]. The different phenotypes associated with *SHOX* duplications (table 2) may be related to their size, position and number of transcriptional enhancers within the duplicated interval [Benito-Sanz et al., 2011]. In the present case, the breakpoint is located 44 kb upstream of *SHOX*, where 5 highly conserved noncoding elements (CNEs) have been identified. All these CNEs are conserved in distantly related species and have enhancer activity in the developing chicken limb [Durand et al., 2010]. Even if all these CNEs are located in the duplicated region of idic(Y), the short stature of this boy may be related to a positional effect of the breakpoint on CNEs, or by disrupted activity of other regulatory sequences not yet characterized.

A literature review indicates that patients with short stature and different extents/positions of *SHOX* duplications are extremely rare. To our knowledge, only 17 cases including our patient have been described (female to male ratio 1.6:1.0; table 2). Multiple/complex Y rearrangements and mosaic cases were excluded. Few clinical data are reported in some studies and other phenotypic

Fig. 2. Possible mechanisms of idic(Y) formation. A double-strand break occurs in the Y chromosome, and the broken ends are joined to stabilize the chromosome. This results in an idic(Y) and an acentric fragment (a). A misalignment, due to palindromic sequences in Y(p), occurs between sister chromatids followed by NAHR. Again this results in an idic(Yp) and an acentric fragment which has the length of Yp (b).

abnormalities were present in some patients (table 2). One girl with partial duplication of exons 2–6a was born small for gestational age [Benito-Sanz et al., 2011], which is a known cause of short stature [Rogol and Hayden, 2014]. Two additional small for gestational age babies with *SHOX* duplication and complex malformations resembling VACTERL association have been described, but their postnatal growth pattern was not shown [Brosens et al., 2014]. Phenotype may be LWD (47%), mainly in par-

tial duplications, or isolated short stature (53%) in both complete and partial duplications, as in the present case (table 2). Madelung deformity was present in a minority of patients (44%), all having partial *SHOX* duplications (table 2). Patients with LWD phenotype or Madelung deformity without short stature, who have a 5' *SHOX* duplication are also described [Thomas et al., 2009; Benito-Sanz et al., 2011]. The causative role of *SHOX* duplication in other phenotypic or neurological abnormalities de-

Table 2. Clinical and genetic features of children with partial or complete *SHOX* duplication and short stature

Authors	Sex	Age, years	Phenotype	Height, SD	Madelung deformity	Genotype	Notes
Iughetti et al. [2010]	M	13.9	ISS	−3.25	no	complete <i>SHOX</i> -3' region	normal birth weight, parents with normal height
D'haene et al. [2010]	–	–	ISS	–	–	–	–
Benito-Sanz et al. [2011]	F	13.0	ISS	−2.57	no	5' region-complete <i>SHOX</i> -3' region	slightly shortened neck
	F	adult	ISS	−2.19	no	5' region-complete <i>SHOX</i>	–
	F	13.8	ISS	−2.29	no	5' region-complete <i>SHOX</i>	–
	F	6.7	ISS	−2.01	no	5' region-partial <i>SHOX</i> (5'-Ex3)	dermatitis atopica
	M	13.0	LWD	−2.25	yes	5' region-partial <i>SHOX</i> (5'-Ex3)	–
	M	10.7	LWD	−1.80	yes	partial <i>SHOX</i> (Ex2–6b)	–
	M	15.5	LWD	−3.88	yes	partial <i>SHOX</i> (Ex2–6a)	–
	F	5.0	LWD	−4.13	yes	partial <i>SHOX</i> (Ex2–6a)	–
	F	13.0	LWD	−2.24	yes	partial <i>SHOX</i> (Ex2–6a)	pyloric stenosis, urethral reflux
	M	10.0	LWD	−2.06	yes	partial <i>SHOX</i> (Ex2–6a)	–
	F	13.5	LWD	−3.95	yes	partial <i>SHOX</i> (Ex2–6a)	–
	F	7.5	LWD	−1.88	no	partial <i>SHOX</i> (Ex2–6a)	precocious puberty (menarche 8 years)
	F	14.0	ISS	−2.40	no	partial <i>SHOX</i> -3' region (Ex4-3')	SGA, premature adrenarche
	F	adult	ISS	−2.10	no	5' region	mental retardation, dysmorphic facies
Present case	M	9.5	ISS	−2.70	no	5' region-complete <i>SHOX</i>	referred normal birth weight, first case treated with GH

ISS = Isolated short stature; SGA = small for gestational age.

scribed in some patients with *SHOX* duplication [Roos et al., 2009; D'haene et al., 2010; Iughetti et al., 2010; Brosens et al., 2014] requires further investigations, assessing the possible extraskelletal effect of this gene. Indeed, a definite genotype/phenotype correlation is currently not possible, due to the limited number of patients and the difficulties in comparing the extent of duplicated regions. In fact, the use of different in-house FISH clones, as well as different commercial kits for the MLPA analysis, determines some variability in probe specificity and localization. In addition, incomplete penetrance and variable expressivity of *SHOX* may play a role.

The effect of GH therapy in short patients with *SHOX* duplications was previously unreported. In our case, recombinant GH therapy induced a catch-up growth in the first year of treatment with an increase of growth velocity similar to that observed in *SHOX* haploinsufficiency [Binder, 2011; Iughetti et al., 2012; Massart et al., 2013], but efficacy in improving adult height and safety will require long-term follow-up.

In conclusion, *SHOX* duplications may be a rare cause of short stature. Although expression studies of *SHOX* are not easy to be performed due to its tissue specificity and temporal regulation, a detailed molecular characterization of the PAR1 region is mandatory when *SHOX* dupli-

cation is found, to better elucidate the correlations between different duplications and their phenotypic consequences. The beneficial effect of GH treatment in this child with *SHOX* duplication and short stature will be confirmed in other studies.

Statement of Ethics

The study was performed according to the Declaration of Helsinki II and standard protocol of short stature investigation in our Departments. Human recombinant GH treatment for *SHOX* gene deficiency was licensed by the Italian Regulatory Agency. Written informed consent was obtained from the parents before clinical, endocrine and genetic investigations.

Disclosure Statement

The authors have no conflicts of interest to declare.

References

- Aksglaede L, Skakkebaek NE, Juul A: Abnormal sex chromosome constitution and longitudinal growth: serum levels of insulin-like growth factor (IGF)-I, IGF binding protein-3, luteinizing hormone, and testosterone in 109 males with 47,XXY, 47,XYY, or sex-determining region of the Y chromosome (SRY)-positive 46,XX karyotypes. *J Clin Endocrinol Metab* 93:169–176 (2008).
- Benito-Sanz S, Barroso E, Heine-Suñer D, Hisado-Oliva A, Romanelli V, et al: Clinical and molecular evaluation of *SHOX*/PAR1 duplications in Léri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). *J Clin Endocrinol Metab* 96:E404–E412 (2011).
- Bertelloni S, Baroncelli GI, Dati E, Ghione S, Baldinotti F, et al: IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the *PTPN11* gene. *Hormones (Athens)* 12:86–92 (2013).
- Binder G: Short stature due to *SHOX* deficiency: genotype, phenotype, and therapy. *Horm Res Paediatr* 75:81–89 (2011).
- Blaschke RJ, Töpfer C, Marchini A, Steinbeisser H, Janssen JW, Rappold GA: Transcriptional and translational regulation of the Léri-Weill and Turner syndrome homeobox gene *SHOX*. *J Biol Chem* 278:47820–47826 (2003).
- Brosens E, de Jong EM, Barakat TS, Eussen BH, D'haene B, et al: Structural and numerical changes of chromosome X in patients with esophageal atresia. *Eur J Hum Genet* 22:1077–1084 (2014).
- Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, et al: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. *J Clin Endocrinol Metab* 93:4210–4217 (2008).
- de Arriba Muñoz A, Domínguez Cajal M, Rueda Caballero C, Labarta Aizpún JI, Mayayo Dehesa E, Ferrández Longás Á: Sitting height/standing height ratio in a Spanish population from birth to adulthood. *Arch Argent Paediatr* 111:309–314 (2013).
- D'haene B, Hellemans J, Craen M, De Schepper J, Devriendt K, et al: Improved molecular diagnostics of idiopathic short stature and allied disorders: quantitative polymerase chain reaction-based copy number profiling of *SHOX* and pseudoautosomal region 1. *J Clin Endocrinol Metab* 95:3010–3018 (2010).
- Durand C, Bangs F, Signolet J, Decker E, Tickle C, Rappold G: Enhancer elements upstream of the *SHOX* gene are active in the developing limb. *Eur J Hum Genet* 18:527–532 (2010).
- Ellison JW, Wardak Z, Young MF, Gehron Robey P, Laig-Webster M, Chiong W: *PHOG*, a candidate gene for involvement in the short stature of Turner syndrome. *Hum Mol Genet* 6:1341–1347 (1997).
- Ghione S, Maestro S, Dati E, Silvestri V, Baroncelli GI, Bertelloni S: Growth impairment and growth hormone-IGF-1 axis in infantile anorexia nervosa. *J Pediatr Endocrinol Metab* 28:999–1001 (2015).
- Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist (Stanford University Press, Stanford 1959).
- Huber C, Rosilio M, Munnich A, Cormier-Daire V, French *SHOX* GeNeSIS Module: High incidence of *SHOX* anomalies in individuals with short stature. *J Med Genet* 43:735–739 (2006).
- Iughetti L, Appio P, Capone L, Madeo S, Predieri B, et al: Short stature homeobox-containing gene and idiopathic short stature. *Expert Rev Endocrinol Metab* 4:241–250 (2009).
- Iughetti L, Capone L, Elsedfy H, Bertorelli R, Predieri B, et al: Unexpected phenotype in a boy with trisomy of the *SHOX* gene. *J Pediatr Endocrinol Metab* 23:159–169 (2010).
- Iughetti L, Vannelli S, Street ME, Pirazzoli P, Bertelloni S, et al: Impaired GH secretion in patients with *SHOX* deficiency and efficacy of recombinant human GH therapy. *Horm Res Paediatr* 78:279–287 (2012).
- Lange J, Skeletsky H, van Daalen SKM, Embry SL, Korver CM, et al: Isodicentric Y chromosomes and sex disorders as byproducts of homologous recombination that maintains palindromes. *Cell* 138:855–869 (2009).
- Marchini A, Rappold G, Schneider KU: *SHOX* at a glance: from gene to protein. *Arch Physiol Biochem* 113:116–123 (2007).
- Massart F, Bizzi M, Baggiani A, Miccoli M: Height outcome of the recombinant human growth hormone treatment in patients with *SHOX* gene haploinsufficiency: a meta-analysis. *Pharmacogenomics* 14:607–612 (2013).
- Pessoa de Queiroz AN, Collett-Solberg PF, Cardoso ME, Jusan RC, Vaisman M, Guimarães MM: IGF-I, IGFBP-3 and ALS generation test in Turner syndrome. *Growth Hormon IGF Res* 17:254–260 (2007).
- Rao E, Weiss B, Fukami M, Rump A, Niesler B, et al: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. *Nat Genet* 16:54–63 (1997).
- Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, et al: Genotypes and phenotypes in children with short stature: clinical indicators of *SHOX* haploinsufficiency. *J Med Genet* 44:306–313 (2007).
- Rogol AD, Hayden GF: Etiologies and early diagnosis of short stature and growth failure in children and adolescents. *J Pediatr* 164 Suppl 5:S1–S14 (2014).
- Roos L, Brøndum Nielsen K, Tümer Z: A duplication encompassing the *SHOX* gene and the downstream evolutionarily conserved sequences. *Am J Med Genet A* 149A:2900–2901 (2009).
- Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V: Genotypes and phenotypes of children with *SHOX* deficiency in France. *J Clin Endocrinol Metab* 97:E1257–E1265 (2012).
- Rosin JM, Abassah-Oppong S, Cobb J: Comparative transgenic analysis of enhancers from the human *SHOX* and mouse *Shox2* genomic regions. *Hum Mol Genet* 22:3063–3076 (2013).
- Thomas NS, Harvey JF, Bunyan DJ, Rankin J, Grigeliuniene G, et al: Clinical and molecular characterization of duplications encompassing the human *SHOX* gene reveal a variable effect on stature. *Am J Med Genet A* 149A:1407–1414 (2009).
- Wolters B, Lass N, Wunsch R, Böckmann B, Austrup F, Reinehr T: Short stature before puberty: which children should be screened for *SHOX* deficiency? *Horm Res Paediatr* 80:273–280 (2013).